Expand CANF Menu
CANF MENU

CANF Latest Press Releases

-- June 2, 2026 --

Can-Fite Reports Positive Clinical Observation in Phase 2a Pancreatic Cancer Study and Highlights Namodenoson's RAS Signaling Inhibition Mechanism Globe Newswire 7:00 AM

-- May 18, 2026 --

Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson's Potential in the Multi-Billion Dollar Canine Osteoarthritis Market Globe Newswire 7:00 AM

-- May 13, 2026 --

Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy Globe Newswire 7:00 AM

-- April 30, 2026 --

Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months Globe Newswire 8:31 AM

-- March 30, 2026 --

Can-Fite's Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026 Globe Newswire 7:20 AM

-- March 26, 2026 --

Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient Globe Newswire 9:27 AM

-- March 17, 2026 --

Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance Globe Newswire 7:47 AM

-- March 4, 2026 --

Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds Globe Newswire 10:25 AM
Can-Fite's Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study Globe Newswire 7:00 AM

-- February 17, 2026 --

Can-Fite Announces Scientific Breakthrough Publication Demonstrating Anti-Obesity Effect of Namodenoson Globe Newswire 7:00 AM

-- February 9, 2026 --

Can-Fite: Receives Canadian Patent Allowance for Namodenoson as an Anti-Obesity Therapy Globe Newswire 7:00 AM

-- February 5, 2026 --

Can-Fite: Patient with Decompensated Liver Cirrhosis Successfully Undergoes Liver Transplantation Following Treatment with Namodenoson Globe Newswire 7:00 AM

-- January 20, 2026 --

Can-Fite Completes Patient Enrollment in Phase 2a Pancreatic Cancer Study of Namodenoson Globe Newswire 7:00 AM
Market Data Delayed 15 Minutes